INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Effective Communication In Pharmacovigilance

Prajakta Pujari*[1], Sonali Magdum[2], Kajal Shinde[3], Darshani Taral[4], Prajakta Chaugule[5], Sadhana Pujari[6], Ravina Kamble[7], Dhanashree Rajput[8], S. S. Patil[9]

[1-8] *Faculty of pharmacy, Dr. J. J. Magdum Pharmacy College, Jaysingpur*
[9]*Principal , Dr. J. J. Magdum Pharmacy College, Jaysingpur*

ARTICLE INFO

Received: 19 Feb 2024
Accepted: 23 Feb 2024
Published: 25 Feb 2024

Keywords:
Drug development, adverse event, Pharmacovigilance, Health Profession.

DOI:
10.5281/zenodo.10702115

ABSTRACT

The science field of pharmacovigilance (PV) is notable for its work on the identification, assessment, mitigation, and prevention of adverse medication responses and issues associated with them, such as allergic reactions. The assessment of the risk vs. benefit medication profile for improved potency with more safety to use various pharmaceuticals in patients suffering from various illnesses is the primary issue of pharmacovigilance. Pharmacovigilance, the process of gathering information and disseminating reports on diverse adverse medication responses among various users, plays a critical role in the healthcare sector in the responsible use of pharmaceuticals in society. India's pharmaceutical business, in terms of capability and ethics, is able to position third globally. In India, a top choice for research and development, new therapeutic compounds, including synthetic and natural ingredients, particular dosage forms, and pharmaceuticals are produced on a big scale. However, for improved safety studies in the pharmaceutical sector, we need a worldwide standardised pharmacovigilance system. This review paper clarifies the significance of excellent communication in the health business and the function it plays in pharmacovigilance.

INTRODUCTION

W. McBride, an Australian physician, officially established pharmacovigilance (PV) in December 1961 through the publication of a case report in the prestigious journal Lancet, in which he raised concerns about a possible link between thalidomide, a popular pregnancy drug, and serious foetal deformities (phocomelia): In pregnant women, thalidomide was administered as an antiemetic and sedative. [1]. The "Programme for International Drug Monitoring" was a pilot initiative launched in 1968 by the World Health Organisation (WHO) with the goal of collecting global data on adverse drug reactions (ADRs). The major goal of the "WHO Programme" was to identify pharmacovigilance signals as early as feasible. A French group of pharmacologists and toxicologists proposed the word

***Corresponding Author:** Prajakta Pujari
Address: *Faculty of pharmacy, Dr. J. J. Magdum Pharmacy College, Jaysingpur*.
Email : rushiwable9321@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

"pharmacovigilance" to describe the actions supporting "The assessment of the risks of side effects potentially associated with drug treatment" in the middle of the 1970s. [2]. Pharmacovigilance is the science of compiling, measuring, analysing, and evaluating data from healthcare professionals and patients on the adverse effects of various medications, vaccines, toxoids, blood products, medical devices, traditional herbal, and synthetic drugs with the goal of gathering data on various threats associated with these molecules and preventing patient harm. To preserve society's confidence, it has become increasingly challenging to maximise medication safety. Pharma Industries must now actively assess medication risks and manage them throughout a product's lifespan, as well as monitor them from development through post-market. [3]. ADRs, which are unanticipated and dangerous medication reactions that happen at prophylactic dosages typically used for the diagnosis or treatment of sickness, or for the regulation of body processes, are of particular importance to pharmacovigilance [4]. It is helpful to continuously monitor pharmacological effects, side effects, contraindications, and absolutely dangerous consequences that, in certain situations, might raise morbidity and mortality in order to enhance the benefits while lowering the dangers. When a medicine is sold and given to a large population, the greatest care and vigilance throughout pre-clinical and clinical investigations, including clinical trials, can assure an absolute safety. Because clinical studies only involve at most a few thousand individuals, new drug compounds are often introduced to the market with relatively few side effects and without adequate time to identify adverse drug responses. To determine the relationship between a medicine and adverse drug reactions (ADRs), post-marketing pharmacovigilance employs tools including data mining and case report analysis. The responsibility to monitor ADRs both during the drug development phase and later on during the lifecycle of a marketed medicine rests with the drug regulatory bodies [5]. The partners in medication safety monitoring practises, including the government, business, hospitals, medical staff, chemists, and patients, typically have a relationship to their survival. [6, 7]. To effectively combat adverse events and meet upcoming challenges in pharmacovigilance, continued collaboration and adherence are important. [8].

SCOPE OF PHARMACOVIGILANCE

The field of pharmacovigilance has grown significantly since the 1972 WHO technical study, and it now serves as a useful clinical and scientific discipline in pharmacy. Pharmacovigilance is crucial to the safe use of a variety of chemical and biological treatments, including vaccinations, sera, and toxoids, in order to prevent unavoidable and unanticipated potential effects. The danger of adverse effects is decreased when medications are taken by trained medical personnel and by individuals who are knowledgeable of how to take their medications. It is crucial that toxicity and side effects be assessed and beneficially shared with experts who have the knowledge to interpret the facts and report appropriately when they manifest, especially when they were previously unknown with the drug in the association. Up to a point, the pharmacovigilance agent is in charge of this function, but they must strive hard to combine the discipline with pharmacy practise for the sake of society. According to the regulations, the pharmaceutical businesses in India are required to take out operations including assembly and advanced reporting of considerably unexpected ADRs in order to complete pharmacovigilance for their accessible items [9]. Figure 1 depicts the unique organisation of pharmacovigilance research in our nation,

including participants at various levels, structural units, and their roles.

IMPORTANCE OF PHARMACOVIGILANCE

In the majority of nations, adverse drug reactions (ADR) are among the top 10 primary causes of mortality. Drug safety monitoring allows for the exploration, prevention, or reduction of ADRs brought on by therapeutic medicines, biologicals, or technologies. It is the process of discovering anticipated and unforeseen adverse drug events during the post marketing period. Good safety monitoring motivates medical professionals to be accountable for the drugs they use. It enhances therapeutic efficacy and boosts their patients' and their own confidence in using medications. If health practitioners are confident in their capacity to diagnose, treat, and prevent such responses, they are more likely to recognise and report significant ADRs.

CLINICAL RESEARCH REGULATION IN INDIA

The conduct of clinical trials is overseen by a variety of regulatory organisations in our nation, along with an ethics committee. In the table that follows, these regulatory organisations are listed along with their functions

.Table No. 1: Regulatory agencies in India

Agencies	Role of agencies
Drug	DCGI Plays key role in implementation of National
Central	CDSCO is operating along with National Pharmacovigilance Advisory Committee to recommend regulatory procedures& guidelines
Department of Biotechnology(DBT)	DBT Provides support for pilot and large-scale trials on agricultural and clinical trials for health care products evaluation and validation.
Ministry	MOEF advisory committee play a role in approving guidelines on data entries of environmental expert's information gained through the clinical trials for health care products and trials for agriculture products.
Central Bureau of Narcotics (CBN)	CBN regularly monitors clinical trials of Narcotics Drugs for compliances related to storage , import, export quotas and movement of drug under investigation.
National Pharmacovigilance Advisory	NPAC aggregate, access and documents adverse drug reaction data to create friendly environment for the regulatory authorities to analyze the drugs before marketing.
Indian Council of Medical Research (ICMR)	ICMR in 1980 introduced the 'Policy Statement on Ethical Considerations involved in Research on Human Subjects' and revised these guidelines in 2000 as 'Ethical guidelines for Biomedical Research on Human Subjects'.
Ministry	MHFW sets standards for pharmaceuticals healthcare devices and medicines in India

DATA SEARCH FOR PV

Two distinct levels of pharmacovigilance are utilised to improve patient safety and health care against numerous medications used, including

stage I:

Pre-Market Surveillance -involves gathering data on negative medication responses from Phase 1 through Phase 3 clinical studies.

Stage II:

Post-Market Surveillance - It entails data gathering in the post-approval stage via the market to identify safety problems.

Premarket Surveillance

Pharmacovigilance has been devoted to speculating about ADRs at the early phases of the drug development process during the pre-marketing period. One of the fundamental methodologies most often used in preclinical in-

vitro substance evaluation using biochemical and tissue culture techniques is safety pharmacology profiling (SPP). This technique is based on the idea that a chemical moiety must bind to a particular target in order for any ADR to manifest in humans, which might lead to any reported adverse effect. However, an experimental report of ADRs is not always appropriate in terms of cost and effectiveness. An extensive range of research activities have been carried out to hypothesise on the majority of potential ADRs using the preclinical properties of the drugs employing SPP models. The classification of the present body of research is based on techniques that target proteins and have chemical structural implications. [10].

post-marketing monitoring Before being approved by the Food and Drug Administration (FDA), a drug must pass a rigorous clinical screening process, but there is a chance that some adverse drug reactions (ADRs) may go undetected due to small, biassed clinical trials in which patients with coexisting conditions like insomnia, diabetes, anxiety, and depression were not included. Premarketing clinical studies cannot be relied upon since they do not give accurate information for a wide range of communities; consequently, post market surveillance must continue. A significant part of assessing newly discovered medications' post-marketing is done through pharmacovigilance. [11, 12]. Prior to the introduction of a new medicine to the market, a research and development process is permitted by the rivalry between the many pharmaceutical firms and the stringent regulatory review procedures. Several distinct data sources conduct post-marketing pharmacovigilance. [13]. The analysis of "signals" is the foundation of pharmacovigilance research. These signals, according to the World Health Organisation, are unrevealed claims that a drug's adverse effects are directly related to how a patient reacts to it. [14].

Spontaneous reporting systems (SRS) are used by physicians and researchers for the creation of thorough signal databases. The usage of electronic SRSs is already widespread in various nations in Europe and the US. In addition to alternative treatments, much research is being done on post-market surveillance of prescriptions and study of physician databases. The majority of the data, however, is not accessible to the general public for explorers, which combined with other hurdles greatly restricts signal discovery. [15- 17]. While drug firms must track and monitor complaints of adverse events made by physicians, attorneys, or patients, the process of detection mostly depends on a doctor's capacity to identify specific symptoms as a medication adverse event. Since the issue of gathering and filtering ADR data from various nodes has previously been researched, physicians continue to use novel approaches in conjunction with other post-drug administration methods to use acquired data. [18]. PV doctors are faced with the task of providing knowledge-oriented tools and services that should assist in getting the best results with a decreased amount of unintended consequences from recorded databases using various approaches capable of gathering medical information. The development and thorough examination of the post-market monitoring database will, in the end, lay the groundwork for the pharmaceutical industry, regulatory agencies, the department of health, and research for enhanced drug analysis. [19].

PHARMACOVIGILANCE STEPS [20]

The primary steps involved in pharmacovigilance are:

- Management of safety data
- Detection of Signal
- Signal evaluation and decisions in accord to safety measures
- Regulatory Actions to protect health of the community
- Providing Information

MANAGEMENT OF SAFETY DATA:

Any therapeutic molecule can result in a serious adverse event, either during the pre- or post-marketing monitoring phases. Any member of the medical team, including a doctor, chemist, nurse, patient, family member, neighbour, or paramedical personnel, may report a major adverse reaction. It takes time to effectively monitor and manage the drug safety data since these undesirable medication effects might happen at any point during the drug molecule's lifespan.

The steps involved in management of safety data are:

- Collection and verification of data
- Adverse drug reactions coding
- Drugs coding
- Assessment of causalities
- Reporting to authorities

COLLECTION AND VERIFICATION OF DATA

Acknowledgement:

All genuine instances must be appropriately recognised by providing an acknowledgement number in order to obtain more information from the reporter if needed.

Duplicate search:

Many safety database software programmes can look for and distinguish between duplicate reports. Basic techniques to identify any duplication include parameters like patient age, patient sex, date of drug exposure, country, etc.

Triage:

According to documented fatalities, life-threatening adverse responses within 7 days, and non-severe adverse reactions within 15 days, triage is used to assign priority to the case for reporting to authorities.

DATA ENTRY:

It is important to thoroughly report the real cases. The utmost caution and secrecy should be used while storing patient information. The ADR reporter's information should be sufficiently clear and thorough to enable easy contact should it be necessary. The brand name, generic name, dosage form, and dose for each drug must be precisely noted. To determine the cause of a negative medication reaction, all side effects must be meticulously documented. This would contain the events' chronology, type, severity, features, findings from investigations and tests, the start date, the course of therapy, its results, and any further medications that could have been used in conjunction with them.

CASE NARRATIVES:

Case summaries comprise a synopsis of a submitted case that contains all pertinent details, such as the medicine and its ADRS. Case reviewers assess and use case narratives to determine the significance of adverse occurrences during the management of safety data.

DRUGS CODING:

It is necessary to code both the suspected drug and the related substances. The World Health Organization's medication lexicon, which is updated three to four times annually by the organization's pharmacovigilance monitoring unit, is frequently used for coding purposes. The WHO lexicon also includes a variety of biotechnological terms, such as special goods, blood products, and diagnostic compounds. For chemical and therapeutic categories, the ATC classifications and the WHO drug record number system are utilised, respectively.

Causality assessment:

In practically every situation, a causality analysis must be carried out, particularly when the severity of the adverse response cannot be proven owing to the delivery of the drug moiety. Several methods are used to evaluate the link between drug exposure and adverse events precisely. These methods are based on the following factors:

The history of interactions between medication administration and negative outcomes

Possibility based on symptoms, lab results, MOA, and other facts Knowledge of pharmacology and how frequently the suspected medication causes bad effects excluding the illness state or concomitant medications for comparable side effects.

Reporting to authorities:

In order to carry out the duties of a pharmacovigilance agent, reporting to the relevant authorities or stakeholders must be done at the appropriate time. This will aid in the prompt release of safety guidelines for any pharmaceutical product post-marketing surveillance and the updating of ADRs.

EFFECTIVE COMMUNICATION IN PHARMACOVIGILANCE [21]

According to pharmacovigilance professionals present globally, active, timely, and efficient communication is crucial in the release of revisions to recommendations for medication safety.

With the following examples of effective communication, safety recommendations may be created:

- Each nation is required to gather, evaluate, and make widely available the safety information on all medication compounds.
- The community's health must be improved via drug safety information.
- Information on the safe use of drug molecules must be provided to the public and healthcare professionals.
- Free access to all the information needed to evaluate and comprehend the risks and advantages of a drug Communication of information and solutions is effective.
- These elements will undoubtedly aid in the creation of medication safety guidelines and the assessment of drug molecules' risk to benefit ratios.

CONCLUSION

The scientific field of pharmacovigilance is notable for its work on the accumulation, assessment, control, and prevention of adverse drug responses and issues that are connected to them, such as allergic reactions. In order to prevent harmful and life-threatening effects of the drug moieties on the community, PV analyst plays a significant role in gathering information from healthcare professionals and patients on the adverse effects of medicines, including biological products like vaccines, toxoids, anticoagulants, herbs, medical devices, and traditional and synthetic medicines. As the pharmaceutical industry in our nation expands daily, we need a solid pharmacovigilance system to monitor medication side effects and guarantee patient safety. Despite all the efforts made by CDSCO to establish a national global pharmacovigilance system, there are still many obstacles to be overcome before pharmacovigilance can be successfully implemented, including a lack of awareness among chemists, nurses, and patients, as well as a lack of technical staff for reporting ADRs. To motivate doctors, chemists, and nurses to report adverse drug reactions (ADRs) that occur in patients, education is urgently needed. An international system for drug safety monitoring will be established thanks to standard pharmacovigilance recommendations for India that were inspired by the EMA's good pharmacovigilance practises.

REFERENCES

1. Mc Bride WG. 1961. Thalidomide and congenital abnormalities. Lancet. 278,358. http://dx.doi.org/10.1016/S0140-6736(61)90927-8
2. Bégaud B, Chaslerie A, Haramburu F. 1994. Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique. PubMed 42, 416-23.

3. WHO. The Importance of Pharmacovigilance, Safety Monitoring of medicinal products. World Health Organization 2002.
4. Report E. Effective communications in Pharmacovigilance. International Conference on Developing Effective Communications in Pharmacovigilance, Erice, Sicily 1997; 24-27.
5. Shuka SS, Gidwani B, Pandey R, Rao SP, Singh V, et al. 2012. Importance of Pharmacovigilance in Indian Pharmaceutical Industry. Asian J. Res. Pharm. Sci. 2, 4-8.
6. 6. Hornbuckle K, Wu H-H, Fung MC. 1999. Evaluation of spontaneous adverse event reports by primary reporter - a 15-year review (1983 to 1997). Drug Inf J. 33, 1117-24.
7. WHO. 2000. Consumer reporting of ADRs. WHO Drug Information. 14, 211-15.
8. Egberts GPG, Smulderes M, De Konig FHP, et al. 1996. Can adverse drug reactions be detected earlier?: a comparison of reports by patients and professionals. BMJ. 313, 530-31. PubMed http://dx.doi.org/10.1136/bmj.313.7056.530
9. Norwood PK, Sampson AR. 1988. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med. 7, 1023-30. PubMed http://dx.doi.org/10.1002/sim.4780071004
10. Whitebread S, Hamon J, Bojanic D, Urban L. 2005. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 10, 1421-33. PubMed http://dx.doi.org/10.1016/S1359-6446(05)03632-9
11. McClure DL. 2009. Improving Drug Safety: Active Surveillance Systems Should be Paramount.
12. Pharmaceutical Medicine. 23, 127-30. http://dx.doi.org/10.1007/BF03256760.
13. Shibata A, Hauben M. Pharmacovigilance, signal detection and signal intelligence overview. Proceedings of the 14th International Conference on Information Fusion (FUSION-2011). Chicago, IL. 2011; pp. 1-7.
14. Lopes P, Nunes T, Campos D, Furlong LI, Bauer-Mehren A, et al. 2013. Gathering and Exploring Scientific Knowledge in Pharmacovigilance. PLoS ONE. 8(12), e83016. PubMed http://dx.doi.org/10.1371/journal.pone.0083016.
15. Stahl M, Edwards IR, Bowring G, Kiuru A, Lindquist M. 2003. Assessing the Impact of Drug Safety Signals from the WHO Database Presented inSIGNAL': Results from a Questionnaire of National Pharmacovigilance Centres. Drug Saf. PubMed 26, 721-27.
16. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279, 1200-05. PubMed http://dx.doi.org/10.1001/jama.279.15.1200
17. Meyboom RHB, Lindquist M, Egberts ACG, Edwards IR. 2002. Signal Selection and Follow- Up in Pharmacovigilance. Drug Saf. 25, 459-65. PubMed http://dx.doi.org/10.2165/00002018200225060-00011.
18. De Bruin ML, Van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG. 2002. Nonsedating antihistamine drugs and cardiac arrhythmias– biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol. 53, 370-74. PubMed http://dx.doi.org/10.1046/j.13652125.2002.01569.x
19. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, et al. 2011. Combining electronic healthcare databases in Europe to allow for largescale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf.

20, 1-11. PubMed http://dx.doi.org/10.1002/pds.2053.

20. Härmark L, van Grootheest AC. 2008. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 64, 743-52. PubMed http://dx.doi.org/10.1007/s00228-008-0475-9.
21. Basic steps in Pharmacovigilance Case Processing [cited on 30/7/2015]; Available at URL:http://www.pharmawisdom.com/Basic-steps-in-Pharmacovigilance-Case rocessing.html

HOW TO CITE: Prajakta Pujari, Sonali Magdum, Kajal Shinde, Darshani Taral, Prajakta Chaugule, Sadhana Pujari, Ravina Kamble, Dhanashree Rajput, S. S. Patil, Effective Communication In Pharmacovigilance, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 2, 684-691. https://doi.org/10.5281/zenodo.10702115